Evidence map›Paper›PMID 41032004›Full record

ArticleCytotherapy2025

Automated vertical wheel bioreactor integrated with process analytics for T-cell manufacturing.

Bryan Wang, Bharat Kanwar, Annie C Bowles-Welch, Walker Byrnes, Paloma Casteleiro Costa, Caroline Filan, Reginald Tran, Theresa Kotanchek, Francisco Robles, Krishnendu Roy and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bryan WangMarcus Center for Therapeutic Cell Characterization and Manufacturing, Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; NSF Engineering Research Center (ERC) for cell Manufacturing Technologies (CMaT), Atlanta, Georgia, USA.
Bharat KanwarGeorgia Tech Research Institute, Georgia Institute of Technology, Atlanta, Georgia, USA; Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Annie C Bowles-WelchMarcus Center for Therapeutic Cell Characterization and Manufacturing, Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA; NSF Engineering Research Center (ERC) for cell Manufacturing Technologies (CMaT), Atlanta, Georgia, USA.
Walker ByrnesGeorgia Tech Research Institute, Georgia Institute of Technology, Atlanta, Georgia, USA; NSF Engineering Research Center (ERC) for cell Manufacturing Technologies (CMaT), Atlanta, Georgia, USA.
Paloma Casteleiro CostaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA.
Caroline FilanWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA.
Reginald TranWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Theresa KotanchekEvolved Analytics LLC, Rancho Santa Fe, California, USA.
Francisco RoblesWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA.
Krishnendu RoyMarcus Center for Therapeutic Cell Characterization and Manufacturing, Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, USA; NSF Engineering Research Center (ERC) for cell Manufacturing Technologies (CMaT), Atlanta, Georgia, USA. Electronic address: Krish.roy@vanderbilt.edu.
Stephen BalakirskyGeorgia Tech Research Institute, Georgia Institute of Technology, Atlanta, Georgia, USA; NSF Engineering Research Center (ERC) for cell Manufacturing Technologies (CMaT), Atlanta, Georgia, USA. Electronic address: Stephen.Balakirsky@gtri.gatech.edu.

Funding

Accessible label-free optical microscopy with quantitative molecular and functional contrastR35GM147437 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Francisco E Robles · 2022 to 2026
$1.9M
NIGMS NIH HHS R35 GM147437
6 · The paper itself

Abstract

BACKGROUND

aimsBiomanufacturing of cell therapies involves highly complex and labor-intensive processes, where process parameters and biological variabilities can significantly influence product quality, reproducibility and therapeutic efficacy. Here, we developed a vertical wheel-based bioreactor platform with automated controls and in-line process analytical technologies (PAT) to demonstrate successful closed-system T cell biomanufacturing.

methodsBy identifying the critical process parameters (CPP), a process development strategy was optimized for expanding primary human unmodified and chimeric antigen receptor (CAR) T cells using multiple activation systems, including degradable microscaffolds.

resultsSpent media analysis combined with symbolic regression identified CPPs, which were validated through small-scale experiments and large-scale expansions in the bioreactor platform. Closed-loop automation with analytics such as real-time imaging also was integrated into the bioreactor platform for continuous monitoring and process control.

conclusionsThis integrated bioreactor platform provides a proof-of-concept design for multiplexed PAT integration, process optimization and feedback-controlled intelligent automation to enable discovery, monitoring and control of critical quality attributes and critical process parameters for cell therapy manufacturing.

Indexed as

BioreactorsCell Culture TechniquesT-LymphocytesAutomationCell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, Chimeric Antigenautomationbioreactor designcell therapy manufacturingprocess analytical technologyprocess developmentT cells

Identifiers

PMID41032004
PMCPMC13431691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.